Clinical trials in Namur – page 3

160 clinical trials in Namur, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Namur at a glance

160

clinical trials

Research sites3

Quick filters

160 trials in Namur

Open in trial search

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Belgium

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Asthma

Recruiting

Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

InvestigationalNo placebo

Study of depemokimab to improve airway function in patients with type 2 eosinophilic asthma

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+3

Recruiting

Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

Registered drugNo placebo

Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Tezepelumab
Sponsor:AstraZeneca AB

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Namur

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory conditions including evaluation of vaccines against RSV, influenza, and treatments for chronic cough and asthma.

RSV and hMPV vaccine studies in elderly
High-dose influenza vaccine assessment
Uncontrolled asthma treatments

Research emphasizes preventive care and management of respiratory infections in vulnerable populations.

02 Oncology Research

Comprehensive studies examining new treatments for various types of cancer, with particular focus on breast, lung, and head and neck cancers.

Advanced breast cancer therapies
Non-small cell lung cancer treatments
Gastric cancer interventions

Trials evaluate novel therapeutic combinations and targeted treatments for specific cancer types.

03 Chronic Conditions

Investigation of treatments for various chronic diseases including kidney disease, narcolepsy, and chronic rhinosinusitis.

Kidney disease management
Sleep disorder treatments
Metabolic condition therapies

Focus on improving quality of life and disease management for long-term conditions.

Back to Belgium All countries